OCGN
HealthcareOcugen, Inc.
$1.45
+$0.07 (+5.07%)
Jan 5, 2026
Price History (1Y)
Analysis
Ocugen, Inc. is a healthcare company operating in the biotechnology industry with a significant presence, as evidenced by its market capitalization of $452.86M and 95 employees. Financially, Ocugen has struggled to achieve profitability, reflected in its negative margins: gross margin at 0.0%, operating margin at -1081.3%, and profit margin also at 0.0%. The company's returns on equity (-289.9%) and assets (-63.7%) are similarly unfavorable. Notably, Ocugen's balance sheet shows a substantial amount of debt ($32.96M) in relation to its cash ($32.56M), indicating a high debt-to-equity ratio (933.03). Ocugen's valuation is characterized by negative price-to-earnings (P/E) and earnings-to-book values, with forward P/E at -6.11 and EV/EBITDA also at -7.88. The company's revenue growth rate of 54.2% year-over-year is notable, but the lack of dividend information and an N/A for payout ratio prevent further analysis in this area.
This analysis is AI-generated for informational purposes only and should not be considered financial advice. Data may be delayed or inaccurate. Always do your own research and consult a qualified financial advisor before making investment decisions.
About Ocugen, Inc.
Ocugen, Inc., a biopharmaceutical company, focuses on discovering, developing, and commercializing novel gene and cell therapies, biologic, and vaccines that improve patients' health. The company's pipeline product includes OCU400, a novel gene therapy product candidate restoring retinal integrity and function across a range of genetically diverse inherited retinal diseases, currently under Phase 3 trials for the treatment of retinitis pigmentosa and Phase 1/2 trials for the treatment of leber congenital amaurosis; OCU410, a gene therapy under phase 1/2 for the treatment of dry age-related macular degeneration (AMD); and OCU410ST, a gene therapy under phase 1/2 for the treatment of Stargardt disease. It is involved in the development of OCU200, a novel fusion protein for the treatment of diabetic macular edema, diabetic retinopathy, and wet age-related macular degeneration; and NeoCart, an autologous chondrocyte-derived neocartilage, currently under Phase 3 studies indicated for the repair of knee cartilage injuries in adult. In addition, the company is developing OCU500, a COVID-19 vaccine; OCU510, a seasonal quadrivalent flu vaccine; and OCU520, a combination quadrivalent seasonal flu and COVID-19 vaccine. It has collaboration agreements with National Institute of Allergy and Infectious Diseases for early clinical studies for the OCU500 program; and a strategic partnership with CanSino Biologics Inc. for manufacturing its modifier gene therapy pipeline product candidates. The company was founded in 2013 and is headquartered in Malvern, Pennsylvania.
Visit website →Key Statistics
- Market Cap
- $452.86M
- P/E Ratio
- N/A
- 52-Week High
- $1.90
- 52-Week Low
- $0.52
- Avg Volume
- 3.91M
- Beta
- 3.50
Company Info
- Industry
- Biotechnology
- Exchange
- NCM
- Country
- United States
- Employees
- 95